Compare Boston Scientific Corporation (BSX) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Prudential PLC — how do they compare? Boston Scientific Corporation trades at $42.71 (market cap $66.37B), while Prudential PLC trades at $28.65 (market cap $35.11B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and Prudential PLC pays a 1.86% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | PUK | |
|---|---|---|
Market Cap | $66.37B | $35.11B |
Sector | Health | Financials |
52-Week High | $108.14 | $33.61 |
52-Week Low | $42.63 | $24.65 |
Enterprise Value | $75.94B | $36.55B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Prudential (PUK) trades at $28.40, up 0.96% with bullish technical signals from moving averages. The stock shows strong fundamentals with a P/E of 9.25, net income margin of 14.52%, and ROE of 21.15%. Recent earnings beat expectations in Q2 and Q4 2025, while analyst consensus leans bullish with 50% buy ratings. Positive news includes JP Morgan's catalyst watch ahead of August results and strategic expansion in India.
Outlook remains positive with improving cash flow trends and debt reduction. Key opportunities include Asia growth exposure and strong profitability metrics. Risks include China regulatory uncertainty and Japan sales suspension impacts. The stock presents value with attractive valuation multiples and analyst support for upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
